Quinoline Derivative Crystal Forms for Stability and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Different crystalline forms of pharmaceutical compounds exhibit varying melting points, solubilities, and stabilities, complicating drug manufacturing and storage stability, and there is a need for a stable crystalline form with improved bioavailability.
Innovation Solution
A crystalline form of 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylamine is developed, characterized by specific X-ray diffraction peaks, and prepared through methods involving mixing with solvents like paraxylene and crystallizing by cooling or suspension, ensuring high purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple crystalline forms exist for the pharmaceutical compound, then the compound exhibits varying melting points, solubilities, and stabilities, but this complicates drug manufacturing and storage stability
Solution Approach 1:
The patent applies parameter changes by modifying crystallization conditions (solvent type, temperature, pH, concentration) to obtain different crystalline forms with distinct physical properties. By systematically varying these parameters, the invention identifies optimal conditions that produce a crystalline form with superior stability and solubility characteristics suitable for pharmaceutical manufacturing
Solution Approach 2:
The patent utilizes phase transitions through controlled crystallization processes where the compound transitions from solution phase to solid crystalline phase. By controlling the crystallization conditions (cooling rate, solvent evaporation, antisolvent addition), the invention directs the formation of specific crystalline polymorphs with desired properties, resolving the contradiction between property variability and manufacturing complexity
2Adaptability or versatility
If multiple crystalline forms exist for the pharmaceutical compound, then different physical properties are exhibited, but storage stability becomes difficult to ensure
Solution Approach 1:
The patent employs parameter changes by adjusting crystallization parameters (temperature, solvent composition, pH, concentration) to produce crystalline forms with enhanced stability. The invention identifies specific parameter ranges that yield crystalline forms with lower hygroscopicity and better thermal stability, ensuring consistent storage performance
Solution Approach 2:
The patent converts the potential harm of polymorphism (instability) into benefit by deliberately selecting and characterizing a specific crystalline form that exhibits superior stability. The invention transforms the complexity of multiple forms into an advantage by identifying the most stable polymorph and establishing controlled crystallization conditions that consistently produce this form, thereby ensuring storage stability
3Stability of the object's composition
If a stable crystalline form is developed, then storage stability and bioavailability are improved, but the preparation process requires precise control
Solution Approach 1:
The patent applies preliminary action by pre-establishing optimized crystallization conditions through systematic screening before scale-up production. The invention determines the optimal solvent system, temperature profile, pH range, and addition rate in advance, creating a robust protocol that maintains stability while reducing the burden on manufacturing precision during actual production
Solution Approach 2:
The patent uses parameter changes to create a process that is both stable and manufacturable. By optimizing parameters such as solvent composition, temperature, pH, and concentration, the invention finds a balance point where the crystallization process yields high stability without requiring excessive precision. The established parameters provide a wide process window that accommodates normal manufacturing variations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline form E demonstrates high purity, stability, low hygroscopicity, improved bioavailability, and solubility, suitable for pharmaceutical applications with enhanced industrial production feasibility.
Implementation Method 1
In an X-ray powder diffraction (XRD) pattern using Cu-Kα radiation, the crystalline form E has diffraction peaks at 2θ in degree of about 3.27, 6.56, 8.84, 9.95, 10.52, 13.10, 13.15, 15.58, 16.68, 17.84 and 18.66
Implementation Method 2
crystallizing by cooling to obtain the crystalline form E
Implementation Method 3
crystallizing by suspension to obtain the crystalline form E
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.